Efficacy of adalimumab in psoriatic arthritis as measured by the disease activity score 28

被引：0
|
作者：
Choy, EHS
Burmester, GR
Bombardieri, S
van den Bosch, F
Sasso, EH
Weinberg, MA
机构：
[1] Kings Coll Hosp London, London, England
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Pisa, Pisa, Italy
[4] Ghent Univ Hosp, B-9000 Ghent, Belgium
[5] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S214 / S214
页数：1
相关论文
共 50 条
  • [1] Efficacy evaluation of adalimumab in psoriatic arthritis by the disease activity score 28 (DAS28)
    Choy, E. H. S.
    Burmester, G. R.
    Bombardieri, S.
    Van den Bosch, F.
    Sasso, E.
    [J]. RHEUMATOLOGY, 2006, 45 : I67 - I68
  • [2] Efficacy of adalimumab measured by the disease activity score 28 (DAS28) and Eular response criteria
    Schiff, M
    Furst, D
    Kavanaugh, A
    Van Riel, P
    Fischkoff, S
    Chartash, E
    Kupper, H
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 170 - 170
  • [3] The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients
    Leeb, Burkhard F.
    Andel, Ingrid
    Sautner, Judith
    Fassl, Christian
    Nothnagl, Thomas
    Rintelen, Bernhard
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (02): : 256 - 260
  • [4] Treatment response in psoriatic arthritis: a comparison between the disease activity scores psoriatic arthritis response criteria and disease activity score-28
    Patel, Khadijah
    Nair, Nisha
    Jani, Meghna
    Chinoy, Hector
    Bluett, James
    Barton, Anne
    Curry, Philippa
    [J]. RHEUMATOLOGY, 2024, 63
  • [5] Efficacy of adalimumab by disease duration in psoriatic arthritis: Subanalysis of ADEPT
    Choy, Ernest
    Gladman, Dafna
    Sasso, Eric
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB186 - AB186
  • [6] The efficacy and safety of adalimumab in psoriatic arthritis
    Ritchlin C.T.
    [J]. Current Rheumatology Reports, 2006, 8 (5) : 329 - 329
  • [7] Concurrent efficacy of adalimumab against skin and joint disease in psoriatic arthritis
    Ritchlin, Christopher
    Mease, Philip J.
    Sasso, Eric
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1819 - 1819
  • [8] Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS)
    Helliwell, Philip S.
    Waxman, Robin
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) : 467 - 468
  • [9] DEVELOPMENT OF A COMPOSITE DISEASE ACTIVITY SCORE IN PSORIATIC ARTHRITIS
    Mumtaz, Aizad
    Gallagher, Phil
    Kirby, Brian
    Coates, Laura C.
    Waxman, Robin
    Helliwell, Philip
    FitzGerald, Oliver
    [J]. RHEUMATOLOGY, 2009, 48 : I57 - I57
  • [10] Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
    Vogelzang, Erik H.
    Kneepkens, Eva L.
    Nurmohamed, Michael T.
    van Kuijk, Arno W. R.
    Rispens, Theo
    Wolbink, Gertjan
    Krieckaert, Charlotte L. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (12) : 2178 - 2182
12345